Updated interim data on an experimental spinal muscular atrophy (SMA) therapy co-developed by PTC Therapeutics Inc., Roche Holding AG and the SMA Foundation show that more than 90 percent of the 21 babies enrolled in the first part of an open-label study experienced a greater than four-point increase on a test designed to measure motor milestone development of patients with SMA type 1.